Stem Cell Therapy for Spinal Cord Injury

Liyi Huang¹,²,*, Chenying Fu³,*, Feng Xiong¹,²,*, Chengqi He¹,², and Quan Wei¹,²

Abstract

Traumatic spinal cord injury (SCI) results in direct and indirect damage to neural tissues, which results in motor and sensory dysfunction, dystonia, and pathological reflex that ultimately lead to paraplegia or tetraplegia. A loss of cells, axon regeneration failure, and time-sensitive pathophysiology make tissue repair difficult. Despite various medical developments, there are currently no effective regenerative treatments. Stem cell therapy is a promising treatment for SCI due to its multiple targets and reactivity benefits. The present review focuses on SCI stem cell therapy, including bone marrow mesenchymal stem cells, umbilical mesenchymal stem cells, adipose-derived mesenchymal stem cells, neural stem cells, neural progenitor cells, embryonic stem cells, induced pluripotent stem cells, and extracellular vesicles. Each cell type targets certain features of SCI pathology and shows therapeutic effects via cell replacement, nutritional support, scaffolds, and immunomodulation mechanisms. However, many preclinical studies and a growing number of clinical trials found that single-cell treatments had only limited benefits for SCI. SCI damage is multifaceted, and there is a growing consensus that a combined treatment is needed.

Keywords

spinal cord injury, stem cells, BM-MSCs, U-MSCs, AD-MSCs, NSCs, NPCs, ESCs, iPSCs, EVs

Introduction

Spinal cord injury (SCI) is a devastating injury that is a source of extensive psychological and economic burden for patients and healthcare systems¹,². It is estimated that SCI affects more than 1 million people in the United States alone, with approximately 17,000 new cases each year³. Current treatments include spinal decompression surgery, treatment for spasticity, and rehabilitation therapy. Despite some advances in clinical management that improve patient’s quality of life⁴,⁵, SCI recovery is very limited, and finding alternative treatments for paralysis remains a top priority.

The time-sensitive and complex pathophysiology make it particularly difficult to investigate therapeutic targets for SCI⁶. After the initial mechanical injury, there are a series of secondary events that worsen the condition of patients⁷. The inflammatory response, gliosis hyperplasia, formation of an inhibitory environment⁸, and scar formation impede axonal regeneration and limit the potential for many therapeutic interventions (Fig. 1).

Cell therapies exhibit neuroprotective and nerve regeneration potential in SCI with different targets and responses to stimuli, such as regulating inflammatory responses, providing nutritional support, and improving plasticity. With these excessive potential mechanisms, various cells from different tissue sources, including bone marrow mesenchymal stem cells (BM-MSCs), umbilical mesenchymal stem cells (U-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), neural stem cells (NSCs), neural progenitor cells (NPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and extracellular vesicles (EVs), were studied. Previous reviews discussed cell therapy for SCI, but there is a lack of systematic elucidation, such as the original function of these cells, the

¹ Department of Rehabilitation Medicine Center, West China Hospital/ West China School of Medicine, Sichuan University, Chengdu, Sichuan, PR China
² Key Laboratory of Rehabilitation Medicine in Sichuan Province, Sichuan University, Chengdu, Sichuan Province, PR China
³ State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
* These authors contributed equally to this article

Submitted: July 14, 2020. Revised: November 15, 2020. Accepted: January 4, 2021.

Corresponding Author:
Quan Wei, Department of Rehabilitation Medicine Center, West China Hospital/West China School of Medicine, Sichuan University, No. 37 Guoxuexiang, Chengdu, Sichuan Province, China.
Email: weiquan@scu.edu.cn

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Figure 1. Pathological characteristics of spinal cord injury at different stages. Neuronal apoptosis and axonal damage are abundant in the acute stage. At the subacute stage, there is a large loss of neurons, axons, and myelin. Activated astrocytes, activated microglia, and macrophages accumulate in the injury site. At the chronic stage, a glial scar and an injury cavity further develop, and the inhibitory microenvironment is formed.
function of modified cells, and the effect of combined therapy. This review performed an up-to-date summary of the current research status, challenges, and prospects for stem cell therapy in SCI to provide an overview of this field9–13 (Table 1).

**Stem Cell Transplantation Strategy**

**Bone Marrow Mesenchymal Stem Cells**

BM-MSCs are partially differentiated progenitor cells that are present in adult bone marrow and support sustained hematopoiesis and bone regeneration. These cells were originally considered pluripotent, with the ability to differentiate into neurons and glial cells. However, additional studies showed that BM-MSC therapy primarily involved in cell fusion and transdifferentiation instead of cell differentiation. Early in vivo studies demonstrated that BM-MSC introduction into the lesion site of spinal cord contusion resulted in the formation of tissue bundles of astrocytes and neuronal predecessors. The introduction of BM-MSCs to the injury site reduced inflammatory reactions, astroglial scarring density, and blood-spinal cord barrier (BSCB) leakage; modulated astroglisis; alleviated neuropathic pain; and improved the functional recovery of hindlimb movement, which may involve the matrix metalloproteinase (MMP) 2/STAT3 pathway.

| Cell type | Effects |
|-----------|---------|
| BM-MSCs   | Secrete neurotrophic factors | 14 |
|           | Promote axonal regeneration | 15 |
|           | Reduce astroglial scarring density | 16 |
|           | Reduce inflammatory reactions | 17 |
|           | Reduce BSCB leakage | 18 |
|           | Regulate autophagy | 19 |
|           | Alleviate neuropathic pain | 20 |
|           | Improve bladder compliance | 21 |
| U-MSCs    | Protect neurons | 22 |
|           | Inhibit glial scars | 23 |
|           | Decrease reactive astrocytes | 24 |
|           | Attenuate ischemic compromise of the spinal cord | 25 |
|           | Alleviate allodynia and hyperalgesia | 26–28 |
|           | Improve muscle tension, bladder function, and urine control | 29 |
|           | Improve SSEP | 30 |
|           | Alleviate neuropathic pain | 30 |
| AD-MSCs   | Promote cell survival and tissue repair | 35 |
|           | Suppress immune activity | 36 |
|           | Secrete anti-inflammatory factors | 36 |
|           | Activate angiogenesis | 37 |
|           | Reduce the formation of cavities | 36 |
|           | Improve sensory and motor functions | 37 |
|           | Ameliorate erectile dysfunction | 31–34 |
| NSCs and NPCs | Increase neuroprotective cytokines | 38,39 |
|           | Improve cell proliferation | 38 |
|           | Increase myelination | 39 |
|           | Modulate the inflammatory response | 41 |
|           | Promote respiratory recovery | 42 |
| ESCs      | Promote astroglisostis | 43,44 |
|           | Enable axons to pass CSPG | 45 |
|           | Support nodal architecture | 46,47 |
|           | Attenuate neurotrophic pain | 48 |
| iPSCs     | Improve neurotrophic factor secretion | 49 |
|           | Promote axonal sprouting | 50 |
|           | Inhibit demyelination | 51,52 |
|           | Promote synapse formation | 53 |
|           | Inhibit glial scarring | 50 |
|           | Reduce lesion size | 54 |
|           | Improve respiratory function | 54 |
| EVs derived from stem cells | Regulate axon regeneration | 55 |
|           | Protect cells from apoptosis | 55 |
|           | Inhibit the activation of astrocytes | 56 |
|           | Inhibit inflammation | 57 |
|           | Reduce injury size | 58 |
|           | Protect the integrity of the BSCB | 59 |

AD-MSC: adipose-derived mesenchymal stem cell; BM-MSC: bone marrow mesenchymal stem cell; BSCB: blood-spinal cord barrier; CSPG: chondroitin sulfate proteoglycan; ESC: embryonic stem cell; EV: extracellular vesicle; iPSC: induced pluripotent stem cell; NPC: neural progenitor cell; NSC: neural stem cell; SSEP: somatosensory-evoked potential; U-MSC: umbilical mesenchymal stem cells.

Further investigation of the BM-MSC intravenous graft model indicated that functional recovery was achieved via the expansion of neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF). NGF and BDNF are key regulators of neuronal differentiation, and VEGF is a key factor in the initiation and maintenance of angiogenesis and vasculogenesis induction. Besides, BM-MSCs may be used as carriers due to their tropism to the injury sites and of interleukin-13 (IL-13), which is an inducer of the anti-inflammatory microglia/macrophage phenotype that significantly improved motor function recovery and decreased demyelination.

Genetic engineering of BM-MSCs is an encouraging method to enhance their therapeutic effect, such as the regulation of specific factors or proteins. Insulin-like growth factor 1 (IGF-1) is an important factor for maintaining the characteristics of NPCs. IGF-1 overexpression of BM-MSCs strengthens antioxidant reactions and improves basso mouse scale (BMS) scores. Other approaches, such as modification of the microRNA-124 gene, silencing the Nogo-66 receptor gene, inhibition of tumor necrosis factor α (TNF-α), and overexpression of neurotrophin-3 (NT-3), the chemokine stromal-derived factor-1, and neurotrophic factor-derived glial cell (GDNF) genes, exhibited better efficacy than original BM-MSCs in motor function and surrounding axon densities. The effects of individual cell transplantation are enhanced by cotransplantation with cells from other sources. These coupling strategies are primarily
focused on MSCs and Schwann cells (SCs) because these cells regulate the microenvironment and improve the survival, differentiation, and proliferation of cotransplanted cells. Various studies reported that MSCs enhanced the effects of SCs and olfactory ensheathing cells (OECs) by decreasing cell apoptosis.

A longitudinal study of BM-MSC-based treatment of cervical SCI patients expanded autologous BM-MSCs and introduced these cells via intradural injection. Improved upper limb motor function and magnetic resonance imaging (MRI) images were observed in 6 of 10 candidates 6 months after transplantation. Six patients with complete SCI received autologous MSC and SC therapy, and the results showed improvements in American Spinal Cord Injury Association (ASIA) grade, bladder compliance, and axonal regeneration. Similarly, a patient with chronic SCI received MSC therapy, and neuropathological function and the ability to walk were improved.

However, a phase III clinical trial demonstrated that single MSC application was safe but had little therapeutic effect. This result may be related to the timing of MSC transplantation because the homing capacity of stem cells is not substantial in chronic SCI. Because of the controversial reports on the extent of patient responses to BM-MSC therapies, the efficacy of BM-MSCs must be further confirmed. Several trials are ongoing, and completion of these studies will provide needed information to initiate a larger investigation of the efficacy of BM-MSC therapies. Overall, BM-MSC therapy is beneficial for SCI recovery by improving the microenvironment of the injury site, enhancing nutritional support, modulating the inflammatory response, and alleviating BSCB leakage. Patients avoid immunoreaction by receiving autologous cell transplantation. Therefore, BM-MSCs have huge potential for SCI treatment due to their reduced immunogenicity and improved availability. However, the therapeutic effects, homing ability, survival, and proliferation of single-cell types are limited. Further studies should focus on these aspects and combinational therapy to improve the efficacy of BM-MSCs.

**Umbilical MSCs**

Recent studies investigated MSCs separated from umbilical cords and adipose tissue. U-MSCs possess the ability to develop into a homogeneous population that expresses neural markers and develops neural phenotypic features. An early study found that U-MSCs migrated into the injury site but not noninjured areas after transplantation, which lays the foundation for their therapeutic effects. Previous studies demonstrated that U-MSCs protected neurons from apoptosis, inhibited the formation of glial scars via regulation of MMP2, attenuated ischemic compromise of the spinal cord, decreased reactive astrocytes, and improved motor function, and alleviated allodynia and hyperalgesia after SCI in animal experiments. U-MSCs demonstrated a better effect for a wide dynamic range of neurons than BM-MSCs. Park and colleagues found that transplanted U-MSCs exhibited a better effect 1 week after SCI than at 12 h and 2 weeks, which indicates a potential time point for the treatment of SCI.

Wnt proteins are involved in neural precursor (NP) differentiation and axon development, and Wnt3a plays important roles in spinal cord dorsal interneuron differentiation. To enhance the efficacy of U-MSCs, researchers established Wnt3a-secreting U-MSCs by gene modification, which showed a better therapeutic effect than primary U-MSCs in SCI rats. Rats that received Wnt3a-MSCs had increased motor function scores and elevated expression of axonal regeneration-related proteins, including choline acetyltransferase, growth-associated protein 43, and microtubule-associated protein 2. Cotransplantation may complement and synergize to improve single-cell therapies. The cotransplantation of human U-MSCs and human NSCs exhibited the best efficacy compared to that of transplantation of hU-MSCs or hNSCs alone.

U-MSCs improved motor function in the lower limb and expanded the atrophied spinal cord after injection into the subarachnoid, intradural, or extradural space of the spinal cord in patients with compressed fractures. After U-MSC transplantation, 7 of 10 patients with thoracolumbar SCI had obvious improvements in movement, muscle tension, bladder function, and urine control compared to those of patients who received rehabilitation therapy alone. The somatosensory-evoked potential (SSEP) and clinical manifestations of neuropathic pain of a patient with 2-year complete cervical SCI were significantly improved and alleviated 1 year after U-MSC transplantation, and the physiological function of myelinated large fibers was reflected by the SSEP. U-MSCs are conveniently obtained because the umbilical cord is generally discarded. U-MSCs are obtained from umbilical blood, perivascular regions, and the umbilical vein subendothelium without ethical issues, and these cells are beneficial in the recovery of SCI via different mechanisms. Further efforts are needed to fully assess the effectiveness of UC-MSC transplantation.

**Adipose-derived MSCs**

AD-MSCs and BM-MSCs share some similarities, such as morphology and cell surface antigen expression, but they differ in proliferation rates and multilineage capabilities. Adipose tissue contains more somatic stem cells than bone marrow, which makes AD-MSCs a good candidate for MSCs, especially with adipose tissue availability.

AD-MSC transplantation demonstrated satisfactory effects in chronic and acute SCI. Intravenous administration of AD-MSCs activates angiogenesis and upregulates ERK and Akt, which improves hindlimb motor function. AD-MSCs also promote cell survival and tissue repair by increasing the expression of beta3-tubulin, BDNF, and ciliary neurotrophic factor (CNTF). AD-MSCs may
protect neurons and ameliorate erectile dysfunction in rats with SCI. In addition to the direct effects, human adipose-derived stem cells transdifferentiate into neuron/motoneuron-like cells, which reduce the formation of cavities and suppress immune activity via the inhibition of astrocyte reactivation and secretion of anti-inflammatory factors. Hypoxic preconditioning-treated AD-MSCs promoted cell survival and increased the expression of marker genes in DsRed-engineered neural stem cells, which enhanced the effect of the combined treatment of stem cells and gene therapy for SCI.

Although AD-MSCs transplantation has been investigated in animal SCI models, large longitudinal clinical trials using stem cells derived from adipose tissue are lacking. Early studies investigating the safety of intravenous AD-MSCs showed no tumorigenicity or other adverse side effects. One study investigated the effects of autologous transplantation of AD-MSCs in 14 patients with SCI who underwent intrathecal transplantation. ASIA sensory and motor scores and electrophysiological evaluations, including MRI and electromyography, were used to determine the effect. After the intervention, 10 patients showed sensory improvement, but the size of the lesion visualized using MRI remained stable. None of the patients treated with AD-MSCs had serious adverse events. Some barriers should be elucidated before clinical translation, such as standard protocols of cell generation, cell characteristics, and clear disclosure of the underlying mechanism, and larger experimental animals that are closer to humans should be used.

**NSCs and NPCs**

NSCs and NPCs are pluripotent cells that are isolated from the subventricular region of the ventricles and hippocampus of the brain and the ependymal region of the central canal of the spinal cord. These cells are capable of differentiating into specific neuronal or glial cells, enhancing remyelination and providing nutritional support, which makes them suitable for cell transplantation therapy in SCI.

NPCs primarily differentiate into oligodendrocytes, increase myelination, and improve hindlimb function. One study also demonstrated that transplantation of NPCs obtained from the subventricular zone promoted respiratory recovery after SCI, which did not work by differentiation. NPC transplantation increased the expression of NGF,CNTF, BDNF, IGF-1, and GDNF, which are beneficial for SCI recovery. NPCs also modulate the inflammatory response via the secretion of reactive macrophages and T cells and neuroprotective cytokines. Previous studies revealed that the transplantation of NPCs during the acute stage demonstrated better efficacy than during the subacute and chronic stages, and transplantation in intact soft tissue may produce better efficacy than transplantation in the injury site during the subacute period.

Modified NSCs may exhibit better therapeutic efficacy than naive cells. Inhibition of leucine-rich repeat and immunoglobulin domain-containing protein (LINGO)-1 in NSCs facilitated neuronal differentiation and recovery in SCI rats. Transplantation of recombinant NSCs with VEGF reduced transient receptor potential vanilloid (TRPV1), increased the release of neurotrophic factors, and promoted neuronal recovery. NSCs with high expression of E-cadherin, a transmembrane adhesion protein, increased the survival of NSCs, decreased the release of inflammatory factors, and promoted functional recovery. Overexpression of the antiapoptotic gene Bcl-XL, upregulation of miR-124, upregulation of NT-3, or polarization toward a more oligodendrogenic fate also achieved better recovery. Mild hypothermia or hypoxia pretreated NSCs showed a more favorable effect on SCI than untreated NSCs by improving cell proliferation and upregulating neurotrophic and growth factors. Combined with MSCs, SCs, and OECs also enhanced neuronal differentiation and cell survival, which further improved motor recovery.

A 2018 study demonstrated that perilesional intramedullary injections of NSCs were safe, but the dose should be verified. Twelve amyotrophic lateral sclerosis patients received transplantation of human spinal cord–derived NPCs, and the results showed that NPC transplantation was safe, which initiated further clinical trials. NPCs showed great potential for SCI treatment, but the functional recovery was limited. Quintessential combinational methods have raised much hope to enhance the efficacy of NPCs. However, rodents were generally used as subjects in previous studies, and some specific larger animals that are closer to humans should be used as experimental subjects to address the problems and move toward clinical translation.

**Embryonic Stem Cells**

ESC-derived definitive neural stem cells express myelin basic protein, support nodal architecture, and display multilayer myelination in SCI animal models. Human embryonic stem cell–derived oligodendrocytes or oligodendrocyte progenitor cells and motoneuron progenitors promote astrogliosis and enhance motor recovery. ESC-derived neural lineage cells enable axons to pass through chondroitin sulfate proteoglycan (CSPG), which is a tremendous barrier to axonal regeneration, and exhibit therapeutic potential for SCI treatment. The expression of...
nerve glial antigen 2 and MMP9\textsuperscript{45} is involved in this process. Transplantation of GABAergic neurons derived from mouse ESCs attenuated neuropathic pain and increased the paw withdrawal threshold and vocalization threshold\textsuperscript{48}.

A clinical study in 2014 showed that human ESC-derived oligodendrocyte progenitor cell transplantation was safe for SCI patients\textsuperscript{125,126}. Another two studies in 2016 demonstrated that SCI patients had restored body functions after intervention with human ESCs\textsuperscript{5,127}, and there were no serious complications. However, the pluripotency of ESCs may result in tumor formation due to their considerable proliferative ability. There may be genetic changes during the cell culture process\textsuperscript{128}. Therefore, it is critical to optimize the differentiation protocol to decrease tumor occurrence and control cell populations to match the different recovery requirements in SCI patients\textsuperscript{129}.

**Induced Pluripotent Stem Cells**

There is significant controversy about ESCs due to their origin. iPSCs, which share the same pluripotent characteristics as ESCs, may neutralize this problem. iPSCs are generated from reprogrammed somatic cells\textsuperscript{12,130–132}, which are separated from accessible tissue, such as autologous skin, which avoids ethical issues, allows autologous cell transplantation, and prevents rejection.

NPs derived from a clone of human iPSCs led to restoration of the injury site\textsuperscript{131}. iPSCs-derived neural stem/progenitor cells (iPSC-NS/PCs) inhibited demyelination\textsuperscript{51,52} and promoted synapse formation\textsuperscript{53} and neurotrophic factor secretion, which improved functional recovery in common marmosets after SCI without tumor formation\textsuperscript{49}. Researchers found that only spinal cord-type NPCs from human iPSCs exhibited efficacy, compared to that with forebrain-type NPCs from human iPSCs, which indicates the importance of the regional identity\textsuperscript{134}. A comparative study demonstrated that iPSC-NPs exhibited the best effect due to their strong graft survival, glial scar inhibition, and axonal sprouting enhancement compared to those of BM-MSCs and NPs derived from an immortalized spinal fetal cell line (SPC-01)\textsuperscript{50}. Different transplantation regions may lead to different effects, and researchers found that intraspinal implantation (cells present in the tissue) may produce better long-term efficacy than intrathecal implantation (paracrine only mechanism)\textsuperscript{135}.

Modified human iPSC-derived astrocytes reduced lesion size and morphological denervation of respiratory phrenic motor neurons and improved respiratory function\textsuperscript{54}. Similarly, γ-secretase inhibitors promoted iPSC-derived NPCs maturation and increased neuronal commitment via regulation of the NOTCH signaling pathway\textsuperscript{136}.

A case report demonstrated that NSCs derived from iPSCs obtained from a healthy 86-year-old male differentiated into neurons and glia, and axons extended long distances and formed synapses after cell transplantation\textsuperscript{137}. Another study suggested that the iCaspase9 gene alleviated adverse events after iPSC-derivative transplantation\textsuperscript{138}. Another study demonstrated that hydrogels modified with an RGD peptide and platelet-derived growth factor (PDGF-A) promoted cell survival and differentiation and reduced teratoma formation\textsuperscript{139}. However, there are opposite results that human iPSC-derived NPCs do not provide beneficial results for SCI therapy. Some of these studies had limitations with graft survival or time to transplant\textsuperscript{140,141}. The tumorigenesis of iPSCs and the prohibitively high cost–benefit for developing treatments\textsuperscript{142} hinder the clinical translation\textsuperscript{143}. It is crucial to develop optimized solutions, including standard protocols for collecting cells, the ideal time for cell delivery, and the safe and effective routes of administration in clinical treatment.

**EVs Derived From Stem Cells**

EVs have come into the spotlight in recent years because of their satisfying therapeutic potential. They are small vesicles (100–1,000 nm) secreted from a variety of cells and have a lipid bilayer membrane. EVs work as cell communication messengers by carrying nucleic acids, proteins, and lipids\textsuperscript{144,145}. EVs are not a single type of vesicle but consist of ectosomes, microvesicles, and exosomes. Exosomes, with diameters of 50–150 nm, are remarkable carriers with low immunogenicity and high biocompatibility\textsuperscript{146}, which protect their cargo from degradation and maintain their biological activity\textsuperscript{147}.

EVs exhibit robust chemotaxis to the injury site and cooperate with neurons. Recent studies reported that MSC-\textsuperscript{57} and NSC-derived\textsuperscript{55} EVs inhibited inflammation, protected cells from apoptosis and reduced injury size, and the mechanism may involve autophagy\textsuperscript{55} and the microRNA-21-5p/FasL gene axis\textsuperscript{58}. Lankford et al. found that exosomes accumulated in the injury sites of the spinal cord and spleen after IV injection\textsuperscript{148,149}. Other studies demonstrated that exosomes derived from BM-MSCs were primarily incorporated in microglial cells, downregulated nuclear factor kappa-B\textsuperscript{150}, protected the integrity of the BSCB\textsuperscript{59}, inhibited the activation of A1 astrocytes\textsuperscript{56}, and played a protective role in rats after SCI.

Exosomes derived from gene-modified stem cells showed more therapeutic potential than exosomes derived from native stem cells. For example, exosomes derived from miR-133b-modified adipose-derived stem cells regulated axon regeneration and improved neurological function after SCI\textsuperscript{151}. Phosphatase and tensin homolog (PTEN) exists in neurons and axons, and it plays an inhibitory role in the growth of axons. Therefore, suppression of PTEN in MSC-derived exosomes showed desirable therapeutic effects on SCI\textsuperscript{151,152}. Similarly, the downregulated expression of phosphatase and tensin homolog pseudogene 1 (PTENP1) in exosomes derived from differentiated P12 cells and MSCs promoted neuronal survival and functional recovery by regulating the expression of miR-19b and miR-21\textsuperscript{153}. There was an obvious decrease in miR-544 expression.
after SCI, and exosomes derived from miR-445-modified MSCs improved functional recovery in rats after SCI\(^1\). MiR-126 loaded in MSC-derived exosomes enhanced angiogenesis, inhibited inflammation, and had an encouraging effect on SCI\(^1\). Similarly, miR-21 deficiency in exosomes derived from MSCs also displayed desirable effects\(^1\). Iron oxide nanoparticles (IONPs) carried by exosome-mimetic nanovesicles (NVs), which were derived from IONP-treated MSCs, enhanced NV homing capacity and further promoted the therapeutic potential of NVs in SCI\(^1\). Since few studies demonstrated the pathophysiology of EVs in SCI, further studies are needed to identify the molecular mechanism and related signaling pathways of the therapeutic effects of EVs. Some nontargeted EVs have also been reported\(^1\), and normalizing the isolation and acquisition of EVs is paramount before translating this therapeutic method to SCI patients clinically\(^1\).

### Other Combinatorial Methods

#### Neuroprotection

Neuroprotective drugs aim to minimize pathological damage and preserve neural tissue. Only methylprednisolone has been clinically proven to provide benefits post-SCI, but it also brings some risks, including gastrointestinal bleeding, wound infection, and thromboembolism\(^1\). However, also brings some risks, including gastrointestinal bleeding, wound infection, and thromboembolism\(^1\). Although stem cell therapy has gained momentum in the field of SCI therapy, it has room for improvement. Biological material use is an encouraging approach for cell therapy by bridging the lesion cavity, replacing damaged extracellular matrices, and integrating the host tissue and transplanted cells. Matrigel is primarily composed of laminin, collagen IV, heparan sulfate proteoglycans, and growth factors that support cell survival and differentiation\(^1\); increase neuronal markers; decrease fibrosis, astroglialisation markers, and inflammatory factors\(^1\), and enhance behavioral recovery in SCI animals. Hydrogels possess a three-dimensional (3D) network structure that provides the benefits regarding electrostatic forces, steric hindrance, and entanglement. These gels are injected or implanted directly because of their soft texture. Laminin-coated hydrogel enhanced the viability of IPSC-NPs and promoted host axon and astrocite growth in the lesion site\(^1\). Ischemia and hypoxia following the primary injury may exacerbate the pathological process of SCI and extremely impede functional recovery after SCI. To address the ischemia and hypoxia in SCI, prevascularized nerve conduits based on the stem cell sheet were designed and implanted in the injury spinal cord, which exhibited satisfactory potential\(^1\). Self-assembling peptides form 3D nanofibers via self-assembly after direct injection to the injury site, act as structural framework, and regulate the microenvironment. The use of NPCs with the self-assembling peptide QL6 reduced cystic cavity formation and inflammation and enhanced synaptic connections by reducing astrogliosis and CSPG, which improved forelimb function in a cervical injury SCI model\(^1\). A previous study reported that chondroitinase ABC (ChABC) enhanced the therapeutic effect of NPCs in SCI, but the ChABC delivery efficiency was unsatisfactory. Nori et al. manufactured NPCS biased toward an oligodendrogenic fate and upgraded the ChABC delivery system via a crosslinked methylcellulose biomaterial, and this combinatorial therapy promoted oligodendrocyte differentiation, remyelination, and synaptic connectivity\(^1\). An N-cadherin-modified linearly ordered collagen scaffold promoted the migration and differentiation of endogenous neural/progenitor stem cells and produced a desirable therapeutic effect in rats after SCI\(^1\). The collagen microchannel scaffold and paclitaxel-liposome combination induced neuronal differentiation of NSCs and growth of neurons and axons, which exhibited great potential for SCI treatment\(^1\). Other scaffolds, such as silk fibroin combined with neurotrophic factors\(^1\), fibrin scaffolds containing growth factors\(^1\), polyelectrolyte delivery of IL-10 and NT-3\(^1\), also promoted the differentiation, proliferation, and viability of transplanted cells, which has desirable therapeutic potential for SCI treatment.

Many kinds of biomaterial scaffolds have been used to deliver MSCs to damaged spinal cords. Unlike NPCs, MSCs likely provide nutritional support, promote axonal regeneration and angiogenesis, and reduce inflammation. Modified

**Biomaterials**

Although stem cell therapy has gained momentum in the field of SCI therapy, it has room for improvement. Biological material use is an encouraging approach for cell therapy by bridging the lesion cavity, replacing damaged extracellular matrices, and integrating the host tissue and transplanted cells. Matrigel is primarily composed of laminin, collagen IV, heparan sulfate proteoglycans, and growth factors that support cell survival and differentiation\(^1\); increase neuronal markers; decrease fibrosis, astroglialisation markers, and inflammatory factors\(^1\), and enhance behavioral recovery in SCI animals. Hydrogels possess a three-dimensional (3D) network structure that provides the benefits regarding electrostatic forces, steric hindrance, and entanglement. These gels are injected or implanted directly because of their soft texture. Laminin-coated hydrogel enhanced the viability of IPSC-NPs and promoted host axon and astrocite growth in the lesion site\(^1\). Ischemia and hypoxia following the primary injury may exacerbate the pathological process of SCI and extremely impede functional recovery after SCI. To address the ischemia and hypoxia in SCI, prevascularized nerve conduits based on the stem cell sheet were designed and implanted in the injury spinal cord, which exhibited satisfactory potential\(^1\). Self-assembling peptides form 3D nanofibers via self-assembly after direct injection to the injury site, act as structural framework, and regulate the microenvironment. The use of NPCs with the self-assembling peptide QL6 reduced cystic cavity formation and inflammation and enhanced synaptic connections by reducing astrogliosis and CSPG, which improved forelimb function in a cervical injury SCI model\(^1\). A previous study reported that chondroitinase ABC (ChABC) enhanced the therapeutic effect of NPCs in SCI, but the ChABC delivery efficiency was unsatisfactory. Nori et al. manufactured NPCS biased toward an oligodendrogenic fate and upgraded the ChABC delivery system via a crosslinked methylcellulose biomaterial, and this combinatorial therapy promoted oligodendrocyte differentiation, remyelination, and synaptic connectivity\(^1\). An N-cadherin-modified linearly ordered collagen scaffold promoted the migration and differentiation of endogenous neural/progenitor stem cells and produced a desirable therapeutic effect in rats after SCI\(^1\). The collagen microchannel scaffold and paclitaxel-liposome combination induced neuronal differentiation of NSCs and growth of neurons and axons, which exhibited great potential for SCI treatment\(^1\). Other scaffolds, such as silk fibroin combined with neurotrophic factors\(^1\), fibrin scaffolds containing growth factors\(^1\), polyelectrolyte delivery of IL-10 and NT-3\(^1\), also promoted the differentiation, proliferation, and viability of transplanted cells, which has desirable therapeutic potential for SCI treatment.

Many kinds of biomaterial scaffolds have been used to deliver MSCs to damaged spinal cords. Unlike NPCs, MSCs likely provide nutritional support, promote axonal regeneration and angiogenesis, and reduce inflammation. Modified
biodegradable chitin conduits in combination with BM-MSC transplantation improved the microenvironment for MSCs, prevented scar formation, and promoted recovery after right spinal cord hemisection injury\(^{185}\). Superparamagnetic iron oxide labeling of BM-MSCs coupled with magnetic guidance offers a promising avenue for the clinical treatment of SCI by enhancing the homing efficiency of cells\(^{186}\). AD-MSCs encapsulated in a fibrin matrix, which is a biopolymer that simulates the natural microenvironment, inhibited injury cavity expansion, increased tissue retention, and promoted recovery of function and structure\(^{187}\). However, some previous studies demonstrated that some biomaterials stimulated a disadvantageous microenvironment in the lesion site, such as a proinflammatory milieu\(^{188}\). Other tissue engineering scaffolds, such as acellular spinal cord scaffolds\(^{189}\), polycaprolactone\(^{190}\), 3D gelatin methacrylate hydrogels\(^{191}\), and 3D fibrin-based scaffolds\(^{192}\), enhanced axonal regeneration and tissue remodeling and improved the therapeutic effect of stem cells. In general, the use of biological materials is a promising combination approach for SCI cell therapy by improving cell implantation, delivering certain factors, promoting neural marker expression and axonal regeneration, inhibiting the inflammatory response, and contacting the injured central nervous system (CNS) tissue.

Challenges and Prospects

Stem cells have neuroregenerative and neuroprotective effects in SCI cell therapy. Cell-based therapies in SCI have different mechanisms in functional recovery, such as immunomodulation, cell replacement nutrition, and scaffold support. However, stem cell therapies present particular safety concerns. First, cell therapy–related immunotoxicity, immunogenicity, and tumorigenicity are often discussed in preclinical studies. Second, limited cell survival and limited integration were common obstacles in previous studies with different experimental designs, including cell number, timing of treatment\(^{193}\), and strategies of transplantation\(^{194}\). Third, it is important to ensure the genetic stability, generation consistency, and storage safety\(^{195}\) of stem cells. The quality and repeatability of stem cell transplantation are critical to clinical translation. Small differences in cell origin and growth conditions may have a significant impact on the outcomes\(^{196,197}\). Fourth, the mechanism of the effects and biological properties should be further investigated to guide the clinical application\(^{187}\). Finally, small sample size, limited supervision, and poor quality are the common problems of most registered clinical trials that hinder the development of stem cell therapy\(^{198}\). Standard protocols are difficult to confirm due to the heterogeneity of the injury type and level, the particular time of treatment, and the different number of transplanted cells.

Encouraging preclinical studies, coupled with publicity, led to early clinical deployment, but the results were mixed. One specific type of stem cell achieves only a limited therapeutic effect. Therefore, many researchers are committed to enhancing the efficacy of stem cells. The use of genetic engineering technology, cell coupling, combinational therapy with neuroprotective agents, trophic factors, biomaterials, and rehabilitation may help improve the therapeutic effectiveness of stem cells in heterogeneous patient populations. Research is needed to optimize their use.

Conclusion

Although cell therapy offers important promise for SCI treatment, there are many obstacles to clinical translation. These obstacles include suitable cell types and sources, cell survival, quality and repeatability of stem cells and optimal transplantation dosage and timing. There are endogenous differences between experimental animals and humans, and much work should be completed before clinical transformation. Each type of stem cell has unique benefits. Previous studies already focused on how to enhance the efficacy of stem cells and made positive achievements. Future treatments may use a variety of novel strategies to address the problems of SCI.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Liyi Huang 🌀 https://orcid.org/0000-0001-7888-9186

References

1. Vismara I, Papa S, Rossi F, Forloni G, Vegliansese P. Current options for cell therapy in spinal cord injury. Trends Mol Med. 2017;23(9):831–849.
2. Bhat IA, Sivanarayanan TB, Somal A, Pandey S, Bharti MK, Panda BS, Indu B, Verma M, Anand J, Sonwane A, Kumar GS, et al. An allogenic therapeutic strategy for canine spinal cord injury using mesenchymal stem cells. J Cell Physiol. 2019;234(3):2705–2718.
3. Center NSCIS. Spinal cord injury (SCI) 2016 facts and figures at a glance. J Spinal Cord Med. 2016;39(4):493–494.
4. Dvorak MF, Noonan VK, Fallah N, Fisher CG, Finkelstein J, Kwon BK, Rivers CS, Ahn H, Paquet J, Tsai EC, Townsend A, et al. The influence of time from injury to surgery on motor recovery and length of hospital stay in acute traumatic spinal cord injury: an observational Canadian cohort study. J Neurotrauma. 2015;32(9):645–654.
5. Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ. 2013;185(6):485–492.
6. Liu D, Li X, Xiao Z, Yin W, Zhao Y, Tan J, Chen B, Jiang X, Dai J. Different functional bio-scaffolds share similar
neurological mechanism to promote locomotor recovery of canines with complete spinal cord injury. Biomaterials. 2019;214:119230.

7. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg. 1991;75(1):15–26.

8. Fehlings MG, Hawryluk GW. Scarring after spinal cord injury. J Neurosurg Spine. 2010;13(2):165–167. discussion 167–168.

9. Kanno H, Pearse DD, Ozawa H, Itoi E, Bunge MB. Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus. Rev Neurosci. 2015;26(2):121–128.

10. Li L, Adnan H, Xu B, Wang J, Wang C, Li F, Tang K. Effects of transplantation of olfactory ensheathing cells in chronic spinal cord injury: a systematic review and meta-analysis. Eur Spine J. 2015;24(5):919–930.

11. Oliveri RS, Bello S, Biering-Sorensen F. Mesenchymal stem cells improve locomotor recovery in traumatic spinal cord injury: systematic review with meta-analyses of rat models. Neurobiol Dis. 2014;62:338–353.

12. Khazaei M, Siddiqui AM, Fehlings MG. The Potential for iPS-derived stem cells as a therapeutic strategy for spinal cord injury: opportunities and challenges. J Clin Med. 2014;4(1):37–65.

13. Stenudd M, Sabelstrom H, Frisen J. Role of endogenous neural stem cells in spinal cord injury and repair. JAMA Neurol. 2015;72(2):235–237.

14. Cizkova D, Rosocha J, Vanicky I, Jergova S, Cizek M. Transplants of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. Cell Mol Neurobiol. 2006;26(7–8):1167–1180.

15. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ, Olson L. Marrowstromal cells form guiding strans in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A. 2002;99(4):2199–2204.

16. Matyas JJ, Stewart AN, Goldsmith A, Han D, Skel RL, Rossignol J, Dunbar GL. Effects of bone-marrow-derived msc transplantation on functional recovery in a rat model of spinal cord injury: comparisons of transplant locations and cell concentrations. Cell Transplant. 2017;26(8):1472–1482.

17. Han D, Wu C, Xiong Q, Zhou L, Tian Y. Anti-inflammatory mechanism of bone marrow mesenchymal stem cell transplantation in rat model of spinal cord injury. Cell Biochem Biophys. 2015;71(3):1341–1347.

18. Matsushita T, Lankford KL, Arroyo EJ, Sasaki M, Neyazi M, Radtke C, Koosis JD. Diffuse and persistent blood-spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells. Exp Neurol. 2015;267:152–164.

19. Tsai MJ, Liou DY, Lin YR, Weng CF, Huang MC, Huang WC, Tseng FW, Cheng H. Attenuating spinal cord injury by conditioned medium from bone marrow mesenchymal stem cells. J Clin Med. 2018;8(1):23.

20. Kakabadze Z, Khipshidze N, Mardaleishvili K, Chutkerashvili G, Chelishvili I, Harders A, Loladze G, Shatirishvili G, Kipshidze N, Chakhunashvili D, Chutkerashvili K. Phase 1 trial of autologous bone marrow stem cell transplantation in patients with spinal cord injury. Stem Cells Int. 2016;2016:6768274.

21. Park JH, Kim DY, Sung IY, Choi GH, Jeon MH, Kim KK, Jeon SR. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012;70(5):1238–1247. discussion 1247.

22. Dasari VR, Veeravalli KK, Tsung AJ, Gondi CS, Gujrati M, Dinh DH, Rao JS. Neuronal apoptosis is inhibited by cord blood stem cells after spinal cord injury. J Neurotrauma. 2009;26(11):2057–2069.

23. Veeravalli KK, Dasari VR, Tsung AJ, Dinh DH, Gujrati M, Fassett D, Rao JS. Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiol Dis. 2009;36(1):200–212.

24. Hu SL, Luo HS, Li JT, Xia YZ, Li L, Zhang LJ, Meng H, Cui KY, Chen Z, Wu N, Lin JK, et al. Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells. Crit Care Med. 2010;38(11):2181–2189.

25. Judas GI, Ferreira SG, Simas R, Sannomiya P, Benicio A, da Silva LF, Moreira LF. Intrathecal injection of human umbilical cord blood stem cells attenuates spinal cord ischaemic compromise in rats. Int J Impot Res. 2014;18(6):757–762.

26. Cui B, Li E, Yang B, Wang B. Human umbilical cord blood-derived mesenchymal stem cell transplantation for the treatment of spinal cord injury. Exp Ther Med. 2014;7(5):1233–1236.

27. Dasari VR, Spomar DG, Li L, Gujrati M, Rao JS, Dinh DH. Umbilical cord blood stem cell mediated downregulation of fas improves functional recovery of rats after spinal cord injury. Neurochem Res. 2008;33(1):134–149.

28. Kaner T, Karadag T, Cirak B, Erken HA, Karabulut A, Kiroglu Y, Akkaya S, Acar F, Coskun E, Genc O, Colakoglu N. The effects of human umbilical cord blood transplantation in rats with experimentally induced spinal cord injury. J Neurosurg Spine. 2010;38(14):453–551.

29. Cheng H, Liu X, Hua R, Dai G, Wang X, Gao J, An Y. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. J Transl Med. 2014;12:253.

30. Hua R, Li P, Wang X, Yang J, Zheng P, Niu X, Li Y, An Y. Evaluation of somatosensory evoked potential and pain rating index in a patient with spinal cord injury accepted cell therapy. Pain Physician. 2016;19(4):E659–E666.

31. Albayrak O, Sener TE, Ersahin M, Ozbas-Turan S, Ekentok C, Tavukcu HH, Cevik O, Cetinel S, Ertas B, Sener G. Mesenchymal stem cell therapy improves erectile dysfunction in experimental spinal cord injury. Int J Impot Res. 2020;32(3):308–316. Epub 2019 Jul 4.

32. Kim Y, Lee SH, Kim WH, Kweon OK. Transplantation of adipose derived mesenchymal stem cells for acute thoracolumbar disc disease with no deep pain perception in dogs. J Vet Sci. 2016;17(1):123–126.
33. Oh JS, Park IS, Kim KN, Yoon DH, Kim SH, Ha Y. Transplantation of an adipose stem cell cluster in a spinal cord injury. Neuroreport. 2012;23(5):277–282.

34. Escalhao CCM, Ramos IP, Hochman-Mendez C, Brunswick THK, Souza SAL, Gutiflen B, Dos Santos Goldenberg RC, Coelho-Sampaio T. Safety of allogeneic canine adipose tissue-derived mesenchymal stem cell intraspinal transplantation in dogs with chronic spinal cord injury. Stem Cells Int. 2017;2017:3053759.

35. Aras Y, Sabanci PA, Kabatas S, Durusu G, Subasi C, Erguven M, Karaez M. The Effects of adipose tissue-derived mesenchymal stem cell transplantation during the acute and subacute phases following spinal cord injury. Turk Neurosurg. 2016;26(1):127–139.

36. Gao S, Guo X, Zhao S, Jin Y, Zhou F, Yuan P, Cao L, Wang J, Qiu Y, Sun C, Kang Z, et al. Differentiation of human adipose-derived stem cells into neuron/motoneuron-like cells for cell replacement therapy of spinal cord injury. Cell Death Dis. 2019;10(8):597.

37. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, Hill CE, Sparling JS, Plemel JR, Plenet WT, Tsai EC, Baptiste D, Smithson LJ, Kawaja MD, et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma. 2011;28(8):1611–1682.

38. Lu P, Jones LL, Snyder EY, Tuszyński MH. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol. 2003;181(2):115–129.

39. Amemori T, Romanyuk N, Jendelova P, Karova K, Zaviskova K, Dubisova J, Kubinova S, Murali R, Sykova E, et al. Human conditionally immortalized neural stem cells improve locomotor function after spinal cord injury in the rat. Stem Cell Res Ther. 2013;4(3):68.

40. Sankavaram SR, Hakim R, Covacu R, Frostell A, Neumann S, Svensson M, Brandin L. Adult neural progenitor cells transplanted into spinal cord injury differentiate into oligodendrocytes, enhance myelination, and contribute to recovery. Stem Cell Reports. 2019;12(5):950–966.

41. Sandhu MS, Ross HH, Lee KZ, Ormerod BK, Reier PJ, Fuller DD. Intraspinal transplantation of subventricular zone-derived neural progenitor cells improves phrenic motor output after spinal cord injury. Stem Cells. 2015;4(4):401–411.

42. Salewski RP, Mitchell RA, Chen C, Fehlings MG. Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury. Stem Cells Dev. 2015;24(1):36–50.

43. Iwai H, Shimada H, Nishimura S, Kobayashi Y, Itakura G, Hori K, Hikishima K, Ebise H, Negishi N, Shibata S Habu S, et al. Allogeneic neural stem/progenitor cells derived from embryonic stem cells promote functional recovery after transplantation into injured spinal cord of nonhuman primates. Stem Cells Transl Med. 2015;4(7):708–719.

44. Ruzicka J, Machova-Urdzickova L, Gillick J, Amemori T, Romanyuk N, Karova K, Zaviskova K, Dubisova J, Kubinova S, Murali R, Sykova E, et al. A comparative study of three different types of stem cells for treatment of rat spinal cord injury. Cell Transplant. 2016;25(3):593–607.

45. Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, Nori S, Hikishima K, Konomi T, Fujiyoshi K, Tsuji O, et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 2012;7(12):e52787.

46. Rong Y, Liu W, Wang J, Fan J, Luo Y, Li L, Kong F, Chen J, Tang P, Cai W. Neural stem cell-derived small extracellular progenitors for application in a rat contusion model of spinal cord injury. Int J Neurosci. 2010;120(4):305–313.

47. vadivelu S, Stewart TJ, Qu Y, Horn K, Liu S, Li Q, Silver J, McDonald JW. NG2+ progenitors derived from embryonic stem cells penetrate glial scar and promote axonal outgrowth into white matter after spinal cord injury. Stem Cells Transl Med. 2015;4(4):401–411.

48. Salewski RP, Mitchell RA, Chen C, Fehlings MG. Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury. Stem Cells Dev. 2015;24(1):36–50.

49. Ruzicka J, Machova-Urdzickova L, Gillick J, Amemori T, Romanyuk N, Karova K, Zaviskova K, Dubisova J, Kubinova S, Murali R, Sykova E, et al. Human conditionally immortalized neural stem cells improve locomotor function after spinal cord injury in the rat. Stem Cell Res Ther. 2013;4(3):68.

50. Sandhu MS, Ross HH, Lee KZ, Ormerod BK, Reier PJ, Fuller DD. Intraspinal transplantation of subventricular zone-derived neural progenitor cells improves phrenic motor output after spinal cord injury. Stem Cells. 2015;4(4):401–411.

51. Salewski RP, Buttigieg J, Mitchell RA, van der Kooi D, Nagy A, Fehlings MG. The generation of definitive neural stem cells from PiggyBac transposon-induced pluripotent stem cells can be enhanced by induction of the NOTCH signaling pathway. Stem Cells Dev. 2013;22(3):383–396.

52. Salewski RP, Mitchell RA, Li L, Shen C, Milekova M, Nagy A, Fehlings MG. Transplantation of induced pluripotent stem cell-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 2012;7(12):e52787.

53. Kawabata S, Tanaka M, Numasawa-Kuroiwa Y, Itakura G, Kobayashi Y, Nishiyama Y, Sugai K, Nishimura S, Iwai H, Isoda M, Shibata S, et al. Grafted human ips cell-derived oligodendrocyte precursor cells contribute to robust remyelination of demyelinated axons after spinal cord injury. Stem Cells Transl Med. 2015;4(7):743–754.

54. Li K, Javed E, Scura D, Hala TJ, Seetharam S, Falnikar A, Richard JP, Chorath A, Maragakis NJ, Wright MC, Lepore AC. Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. Exp Neurol. 2015;271:479–492.
vesicles attenuate apoptosis and neuroinflammation after traumatic spinal cord injury by activating autophagy. Cell Death Dis. 2019;10(5):340.

56. Liu W, Wang Y, Gong F, Rong Y, Luo Y, Tang P, Zhou Z, Zhou Z, Xu T, Jiang T, Yang S. Exosomes derived from bone mesenchymal stem cells repair traumatic spinal cord injury by suppressing the activation of al neurotoxic reactive astrocytes. J Neurotrauma 2019;36(3):469–484.

57. Sun G, Li G, Li D, Huang W, Zhang R, Zhang H, Duan Y, Wang B. hucMSC derived exosomes promote functional recovery in spinal cord injury mice via attenuating inflammation. Mater Sci Eng C Mater Biol Appl. 2018;89:194–204.

58. Zhou X, Chu X, Yuan H, Qiu J, Zhao C, Xin D, Li T, Ma W, Wang H, Wang Z, Wang D. Mesenchymal stem cell derived EVs mediate neuroprotection after spinal cord injury in rats via the microRNA-21-5p/FaslL gene axis. Biomed Pharmacother. 2019;115:108818.

59. Lu Y, Zhou Y, Zhang R, Wen L, Wu K, Li Y, Yao Y, Duan R, Jia Y. Bone Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Recovery Following Spinal Cord Injury via Improvement of the Integrity of the Blood-Spinal Cord Barrier. Front Neurosci. 2019;13:209.

60. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010;21(9):1045–1056.

61. Kim C, Kim HJ, Lee H, Lee H, Lee SJ, Lee ST, Yang SR, Chung CK. Mesenchymal stem cell transplantation promotes functional recovery through MMP2/STAT3 related astrogliosis after spinal cord injury. Int J Stem Cells. 2019;12(2):331–339.

62. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549–580.

63. Liu F, Xuan A, Chen Y, Zhang J, Xu L, Yan Q, Long D. Combined effect of nerve growth factor and brain-derived neurotrophic factor on neuronal differentiation of neural stem cells and the potential molecular mechanisms. Mol Med Rep. 2014;10(4):1739–1745.

64. Dooley D, Lemmens E, Vangansweinkel T, Le Blon D, Hoornaert C, Ponsaerts P, Hendrix S. Cell-Based delivery of interleukin-13 directs alternative activation of macrophages resulting in improved functional outcome after spinal cord injury. Stem Cell Reports. 2016;7(6):1099–1115.

65. Allahdadi KJ, de Santana TA, Santos GC, Azevedo CM, Mota RA, Nonaka CK, Silva DN, Valim CXR, Figueira CP, Dos Santos WLC, do Espirito Santo RF, et al. IGF-1 overexpression improves mesenchymal stem cell survival and promotes neurological recovery after spinal cord injury. Stem Cell Res Ther. 2019;10(1):146.

66. Song JL, Zheng W, Chen W, Qian Y, Ouyang YM, Fan CY. Lentivirus-mediated microRNA-124 gene-modified bone marrow mesenchymal stem cell transplantation promotes the repair of spinal cord injury in rats. Exp Mol Med. 2017;49(5):e332.

67. Li Z, Zhang Z, Zhao L, Li H, Wang S, Shen Y. Bone marrow mesenchymal stem cells with Nogo-66 receptor gene silencing for repair of spinal cord injury. Neural Regen Res. 2014;9(8):806–814.

68. Peng RJ, Jiang B, Ding XP, Huang L, Liao YW, Peng G, Cheng Q, Xi J. Effect of TNF-alpha inhibition on bone marrow-derived mesenchymal stem cells in neurological function recovery after spinal cord injury via the wnt signaling pathway in a rat model. Cell Physiol Biochem. 2017;42(2):743–752.

69. Stewart AN, Kendzierski G, Deak ZM, Bartosek NC, Rezmer BE, Jenrow K, Rossignol J, Dunbar GL. Transplantation of mesenchymal stem cells that overexpress NT-3 produce motor improvements without axonal regeneration following complete spinal cord transections in rats. Brain Res. 2018;1699:19–33.

70. Stewart AN, Matyas JJ, Welchko RM, Goldsmith AD, Zeiler SE, Hochgeschwender U, Lu M, Nan Z, Rossignol J, Dunbar GL. SDF-1 overexpression by mesenchymal stem cells enhances GAP-43-positive axonal growth following spinal cord injury. Restor Neurol Neurosci. 2017;35(4):395–411.

71. Shaheznaz M, Mansour RN, Nazari B, Hassannia H, Hosseini F, Mahboudi H, Eftekary M, Khehtari M, Veshkini A, Ahmad Vaseghi A, Endarami SE. Improved stem cell therapy of spinal cord injury using GDNF-overexpressed bone marrow stem cells in a rat model. Biologicals. 2017;50:73–80.

72. Oraee-Yazdani S, Hafizi M, Atashi A, Ashrafi F, Seddighi AS, Hashemi SM, Seddighi A, Soleimani M, Zali A. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016;54(2):102–109.

73. Ge L, Liu K, Liu Z, Lu M. Co-transplantation of autologous OM-MSCs and OM-OECs: a novel approach for spinal cord injury. Rev Neurosci. 2016;27(3):259–270.

74. Oh SK, Choi KH, Yoo JY, Kim DY, Kim SJ, Jeon SR. A Phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury. Neurosurgery. 2016;78(3):436–447; discussion 447.

75. Park HC, Shin YS, Ha Y, Yoon SH, Park SR, Choi BH, Park HS. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng. 2005;11(5–6):913–922.

76. Sykova E, Homola A, Mazanc R, Lachmann H, Konradova SL, Kobylka P, Padr R, Neuwirth J, Komrskova J, Vavra V, Stulik J, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006;15(8–9):675–687.

77. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun. 2005;332(2):370–379.

78. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017–1026.

79. Goodwin HS, Bicknese AR, Chien SN, Bogueki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat,
and neural markers. Biol Blood Marrow Transplant. 2001;7(11):581–588.
80. Saporta S, Kim JJ, Willing AE, Fu ES, Davis CD, Sanberg PR. Human umbilical cord blood stem cells infusion in spinal cord injury: engraftment and beneficial influence on behavior. J Hematother Stem Cell Res. 2003;12(3):271–278.
81. Park SS, Byeon YE, Ryu HH, Kang BI, Kim Y, Kim WH, Kang KS, Han HJ, Kweon OK. Comparison of canine umbilical cord blood-derived mesenchymal stem cell transplantation times: involvement of astrogliosis, inflammation, intracellular actin cytoskeleton pathways, and neurotrophin-3. Cell Transplant. 2011;20(11–12):1867–1880.
82. Seo DK, Kim JH, Min J, Yoon HH, Shin ES, Kim SW, Jeon SR. Enhanced axonal regeneration by transplanted Wnt3a-secreting human mesenchymal stem cells in a rat model of spinal cord injury. Acta Neurochir (Wien). 2017;159(5):947–957.
83. Hu JG, Wang XF, Deng LX, Liu NK, Gao X, Chen JH, Zhou FC, Xu XM. Cotransplantation of glial restricted precursor cells and Schwann cells promotes functional recovery after spinal cord injury. Cell Transplant. 2013;22(12):2219–2236.
84. Sun L, Wang F, Chen H, Liu D, Qu T, Li X, Xu D, Liu F, Yin Z, Chen Y. Co-Transplantation of human umbilical cord mesenchymal stem cells and human neural stem cells improves the outcome in rats with spinal cord injury. Cell Transplant. 2019;28(7):893–906.
85. Kang KS, Kim SW, Oh YH, Yu JW, Kim KY, Park HK, Song CH, Han H. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy. 2005;7(4):368–373.
86. Danisovic L, Varga I, Polak S, Ulicna M, Hlavackova L, Bohmer D, Vojtassak J. Comparison of in vitro chondrogenic potential of human mesenchymal stem cells derived from bone marrow and adipose tissue. Gen Physiol Biophys. 2009;28(1):56–62.
87. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P, Chen I, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174(3):101–109.
88. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–228.
89. Oh JS, Ha Y, An SS, Khan M, Pennant WA, Kim HJ, Yoon DH, Lee M, Kim KN. Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci Lett. 2010;472(3):215–219.
90. Hur JW, Cho TH, Park DH, Lee JB, Park JY, Chung YG. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial. J Spinal Cord Med. 2016;39(6):655–664.
91. Emgard M, Piao J, Aineskog H, Liu J, Calzarossa C, Odember J, Holmberg L, Samuelsson EB, Bezubik B, Vincent PH, Falci SP, et al. Neuroprotective effects of human spinal cord-derived neural precursor cells after transplantation to the injured spinal cord. Exp Neurol. 2014;253:138–145.
92. Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Peterson AC, Reynolds BA. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci. 1996;16(23):7599–7609.
93. Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433–1438.
94. Parr AM, Kulbatski I, Zahir T, Wang X, Yue C, Keating A, Tator CH. Transplanted adult spinal cord-derived neural stem/progenitor cells promote early functional recovery after spinal cord injury. Neuroscience. 2008;155(3):760–770.
95. Gritti A, Frolichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF, Bjornson CR, Vescovi AL. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci. 1999;19(9):3287–3297.
96. Chen MS, Lin HK, Chiu H, Lee DC, Chung YF, Chiu IM. Human FGF1 promoter is active in ependymal cells and dopaminergic neurons in the brains of F1B-GFP transgenic mice. Dev Neurobiol. 2015;75(3):232–248.
97. Eftekharpour E, Karimi-Abdolrezaae S, Wang J, El Beheiry H, Morshhead C, Fehlings MG. Myelination of congenitally dysmyelinated spinal cord axons by adult neural precursor cells results in formation of nodes of Ranvier and improved axonal conduction. J Neurosci. 2007;27(13):3416–3428.
98. Mothe AJ, Tator CH. Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination. Exp Neurol. 2008;213(1):176–190.
99. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006;7(5):395–406.
100. Liu Y, Zhou Y, Zhang C, Zhang F, Hou S, Zhong H, Huang H. Optimal time for subarachnoid transplantation of neural progenitor cells in the treatment of contusive spinal cord injury. Neural Regen Res. 2013;8(5):389–396.
101. Piltti KM, Salazar DL, Uchida N, Cummings BJ, Anderson AJ. Safety of epicenter versus intact parenchyma as a transplantation site for human neural stem cells for spinal cord injury therapy. Stem Cells Transl Med. 2013;2(3):204–216.
102. Chen N, Cen JS, Wang J, Qin G, Long L, Wang L, Wei F, Xiang Q, Deng DY, Wan Y. Targeted inhibition of leucine-rich repeat and immunoglobulin domain-containing protein 1 in transplanted neural stem cells promotes neuronal differentiation and functional recovery in rats subjected to spinal cord injury. Crit Care Med. 2016;44(3):e146–e157.
103. Zeng Y, Han H, Tang B, Chen J, Mao D, Xiong M. Transplantation of recombinant vascular endothelial growth factor (vegf)189-neural stem cells downregulates transient receptor potential vanilloid 1 (trpv1) and improves motor outcome in spinal cord injury. Med Sci Monit. 2018;24:1089–1096.
104. Chen D, Hu S, Liu J, Li S. E-cadherin regulates biological behaviors of neural stem cells and promotes motor function recovery following spinal cord injury. Exp Ther Med. 2019;17(3):2061–2070.

105. Lee SI, Kim BG, Hwang DH, Kim HM, Kim SU. Overexpression of Bel- XL in human neural stem cells promotes graft survival and functional recovery following transplantation in spinal cord injury. J Neurosci Res. 2009;87(14):3186–3197.

106. Xu W, Li P, Qin K, Wang X, Jiang X. miR-124 regulates neural stem cells in the treatment of spinal cord injury. Neurosci Lett. 2012;529(1):12–17.

107. Kusano K, Enomoto M, Hirai T, Tsoulfas P, Sotome S, Shinomiya K, Okawa A. Transplanted neural progenitor cells expressing mutant NT3 promote myelination and partial hindlimb recovery in the chronic phase after spinal cord injury. Biochem Biophys Res Commun. 2010;393(4):812–817.

108. Nagoshi N, Khazaei M, Ahlfors JE, Ahuja CS, Nori S, Wang J, Shibata S, Fehlings MG. Human spinal oligodendroglial neural progenitor cells promote functional recovery after spinal cord injury by axonal remyelination and tissue sparing. Stem Cells Transl Med. 2018;7(11):806–818.

109. Wang D, Liang J, Zhang J, Liu S, Sun W. Mild hypothermia combined with a scaffold of NgR-silenced neural stem cells/Schwann cells to treat spinal cord injury. Neural Regen Res. 2014;9(24):2189–2196.

110. Fan WL, Liu P, Wang G, Pu JG, Xue X, Zhao JH. Transplantation of hypoxic preconditioned neural stem cells benefits functional recovery via enhancing neurotrophic secretion after spinal cord injury in rats. J Cell Biochem. 2018;119(6):4339–4351.

111. Oh JS, Kim KN, An SS, Pennant WA, Kim HJ, Gwak SJ, Yoon DH, Lim MH, Choi BH, Ha Y. Cotransplantation of mouse neural stem cells (mNSCs) with adipose tissue-derived mesenchymal stem cells improves mNSC survival in a rat spinal cord injury model. Cell Transplant. 2011;20(6):837–849.

112. Niapour A, Karamali F, Nemati S, Taghipour Z, Mandari M, Nasr-Esfahani MH, Baharvand H. Cotransplantation of human embryonic stem cell-derived neural progenitors and Schwann cells in a rat spinal cord contusion injury model elicits a distinct neurogenesis and functional recovery. Cell Transplant. 2012;21(5):827–843.

113. Wang G, Ao Q, Gong K, Zuo H, Gong Y, Zhang X. Synergistic effect of neural stem cells and olfactory ensheathing cells on repair of adult rat spinal cord injury. Cell Transplant. 2010;19(10):1325–1337.

114. Levi AD, Okonkwo DO, Park P, Jenkins AL 3rd, Kurpad SN, Parr AM, Ganju A, Aarabi B, Kim D, Casha S, Fehlings MG, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018;82(4):562–575.

115. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3):363–373.

116. Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C, Feldman EL. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012;30(6):1144–1151.

117. Rosenzweig ES, Brock JH, Lu P, Kumamaru H, Salegio EA, Kadoya K, Weber JL, Liang JJ, Moseanko R, Hawbecker S, Huie JR, et al. Restorative effects of human neural stem cell grafts on the primate spinal cord. Nature Medicine. 2018;24(4):484–490.

118. Koch P, Opitz T, Steinbeck JA, Ladewig J, Brustle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc Natl Acad Sci U S A. 2009;106(9):3225–3230.

119. Shin S, Mitalipova M, Noggle S, Tibbits D, Venable A, Rao R, Stice SL. Long-term proliferation of human embryonic stem cell-derived neural progenitors allows neurogenesis in the rats with defined culture conditions. Stem Cells. 2006;24(1):125–138.

120. Guarino AT, McKinnon RD. Reprogramming cells for brain repair. Brain Sci 2013;3(3):1215–1228.

121. Lee TH. Functional effect of mouse embryonic stem cell implantation after spinal cord injury. J Exerc Rehabil. 2013;9(2):230–233.

122. Cui YF, Xu JC, Hargus G, Jakovcevski I, Schachner M, Bernreuther C. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery after spinal cord injury in mice. PLoS One. 2011;6(3):e17126.

123. Rowland JW, Lee JJ, Salewski RP, Eftekharpour E, van der Kooy D, Fehlings MG. Generation of neural stem cells from embryonic stem cells using the default mechanism: in vitro and in vivo characterization. Stem Cells Dev. 2011;20(11):1829–1845.

124. Alsanie WF, Niclis JC, Petratos S. Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives. Stem Cells Dev. 2013;22(18):2459–2476.

125. Shroff G, Dhanda Titus J, Shroff R. A review of the emerging potential therapy for neurological disorders: human embryonic stem cell therapy. Am J Stem Cells. 2017;6(1):1–12.

126. Scott CT, Magnus D. Wrongful termination: lessons from the Geron clinical trial. Stem Cells Transl Med. 2014;3(12):1398–1401.

127. Shroff G. Human embryonic stem cell therapy in chronic spinal cord injury: a retrospective study. Clin Transl Sci. 2016;9(3):168–175.

128. Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, Hovatta O, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol. 2010;28(4):371–377.

129. Marichal N, Garcia G, Radmilovich M, Trujillo-Cenoz O, Russo RE. Spatial domains of progenitor-like cells and functional complexity of a stem cell niche in the neonatal rat spinal cord. Stem Cells. 2012;30(9):2020–2031.
130. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872.

131. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.

132. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451(7175):141–146.

133. Romanyuk N, Amemori T, Turnovcova K, Prochazka P, Ontemiente B, Sykova E, Jendelova P. Beneficial effect of human induced pluripotent stem cell-derived neural precursors in spinal cord injury repair. Cell Transplant. 2015;24(9):1781–1797.

134. Kajikawa K, Imaiizumi K, Shinozaki M, Shibata S, Shindo T, Kitagawa T, Shibata R, Kamata Y, Kojima K, Nagoshi N, Matsumoto M, et al. Cell therapy for spinal cord injury by using human iPS-derived region-specific neural progenitor cells. Mol Brain. 2020;13(1):120.

135. Amemori T, Ruzicka J, Romanyuk N, Jhanwar-Uniyal M, Sykova E, Jendelova P. Comparison of intraspinal and intrathecal implantation of induced pluripotent stem cell-derived neural precursors for the treatment of spinal cord injury in rats. Stem Cell Res Ther. 2015;6:257.

136. Okubo T, Iwanami A, Kohiyama J, Itakura G, Kawabata S, Nishiyama Y, Sugai K, Ozaki M, Iida T, Matsubayashi K, Matsumoto M, et al. Pretreatment with a gamma-secretase inhibitor prevents tumor-like overgrowth in human iPS-derived transplants for spinal cord injury. Stem Cell Reports. 2016;7(4):649–663.

137. Lu P, Woodruff G, Wang Y, Graham L, Hunt M, Wu D, Boehle E, Ahmad R, Poplawski G, Brock J, Goldstein LS, et al. Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury. Neuron 2014;83(4):789–796.

138. Itakura G, Kawabata S, Ando M, Nishiyama Y, Sugai K, Ozaki M, Iida T, Okubo T, Kojima K, Kashiwagi R, Yasutake K, et al. Fail-safe system against potential tumorigenicity after transplantation of iPS derivatives. Stem Cell Reports 2017;8(3):673–684.

139. Fuhrmann T, Tam RY, Ballarin B, Coles B, Elliott Donaghue I, van der Kooy D, Nagy A, Tator CH, Morshead CM, Sitchet MS. Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model. Biomaterials. 2016;83:23–36.

140. Pomeschik Y, Puttonen KA, Kidin I, Ruponen M, Lehtonen S, Malm T, Akesson E, Hovatta O, Koistinaho J. Transplanted human induced pluripotent stem cell-derived neural progenitor cells do not promote functional recovery of pharmacologically immunosuppressed mice with contusion spinal cord injury. Cell Transplant. 2015;24(9):1799–1812.

141. Nutt SE, Chang EA, Suhr ST, Schlosser LO, Mondello SE, Moritz CT, Cibelli JB, Horner PJ. Caudalized human iPSC-derived neural progenitor cells produce neurons and glia but fail to restore function in an early chronic spinal cord injury model. Exp Neurol. 2013;248:491–503.

142. Fischer I, Dulin JN, Lane MA. Transplanting neural progenitor cells to restore connectivity after spinal cord injury. Nat Rev Neurosci. 2020;21(7):366–383.

143. Lopez-Serrano C, Torres-Espin A, Hernandez J, Alvarez-Palomo AB, Requena J, Gasull X, Edel MJ, Navarro X. Effects of the post-spinal cord injury microenvironment on the differentiation capacity of human neural stem cells derived from induced pluripotent stem cells. Cell Transplant. 2016;25(10):1833–1852.

144. Torralba D, Baixauli F, Villarroya-Beltri C, Fernandez-Delgado I, Latorre-Pellicer A, Acin-Perez R, Martin-Cofreces NB, Jaso-Tamame AL, Iborra S, Jorge I, Gonzalez-Aseguiñola G, et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts. Nat Commun. 2018;9(1):2658.

145. Tkach M, Thery C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–1232.

146. Wang X, Botchway BOA, Zhang Y, Yuan J, Liu X. Combination treatment of bioscaffolds and extracellular vesicles in spinal cord injury. Frontiers in Molecular Neuroscience. 2019;12:81.

147. Taylor DD, Gercel-Taylor C. Exosome platform for diagnosis and monitoring of traumatic brain injury. Philos Trans R Soc Lond B Biol Sci. 2014;369(1652):20130503.

148. Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askernase PW, Kocsis JD. Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One. 2018;13(1):e0190358.

149. All AH, Bazley FA, Gupta S, Pashai N, Hu C, Pourmorteza A, Kerr C. Human embryonic stem cell-derived oligodendrocyte progenitors aid in functional recovery of sensory pathways following contusive spinal cord injury. PLoS One. 2012;7(10):e47645.

150. Zhao C, Zhou X, Qiu J, Xin D, Li T, Chu X, Yuan H, Wang H, Wang Z, Wang D. Exosomes derived from bone marrow mesenchymal stem cells inhibit complement activation in rats with spinal cord injury. Drug Des Devel Ther 2019;13:e40190358.

151. Guo S, Perets N, Betzer O, Ben-Shaul S, Sheinin A, Michaelevski I, Popovtzer R, Ofen D, Levenberg S. Intranasal delivery of mesenchymal stem cell-derived exosomes loaded with phosphatase and tensin homolog sima repairs complete spinal cord injury. ACS nano. 2019;13(9):10015–10028.

152. Kang J, Zhang C, Zhi W, Wang Y, Liu J, Wu F, Xu G. Stem-like cells of various origins showed therapeutic effect to improve the recovery of spinal cord injury. Artif Cells Nanomed Biotechnol. 2020;48(1):627–638.

153. Wang Z, Song Y, Han X, Qu P, Wang W. Long noncoding RNA PTENP1 affects the recovery of spinal cord injury by regulating the expression of miR-19b and miR-21. J Cell Physiol. 2019;235(4):3634–3645.
154. Li C, Li X, Zhao B, Wang C. Exosomes derived from miR-544-modified mesenchymal stem cells promote recovery after spinal cord injury. Arch Physiol Biochem. 2020;126(4):369–375.

155. Huang JH, Xu Y, Yin XM, Lin FY. Exosomes derived from miR-126-modified mcscs promote angiogenesis and neurogenesis and attenuate apoptosis after spinal cord injury in rats. Neuroscience. 2019;424:133–145.

156. Ji W, Jiang W, Li M, Li J, Li Z. miR-21 deficiency contributes to the impaired protective effects of obese rats mesenchymal stem cell-derived exosomes against spinal cord injury. Biochimie. 2019;167:171–178.

157. Kim HY, Kumar H, Jo MJ, Kim J, Yoon JK, Lee JR, Kang M, Choo YW, Song SY, Kwon SP, Hyeon T, et al. Therapeutic efficacy-potentiated and diseased organ-targeting nanovesicles derived from mesenchymal stem cells for spinal cord injury treatment. Nano Lett. 2018;18(8):4965–4975.

158. Osier N, Motamedei V, Edwards K, Puccio A, Diaz-Arrastia R, Kenney K, Gill J. Exosomes in Acquired Neurological Disorders: New Insights into Pathophysiology and Treatment. Mol Neurobiol. 2018;55(12):9280–9293.

159. Patel DB, Santoro M, Born LJ, Fisher JP, Jay SM. Towards rationally designed biomimicking of therapeutic extracellular vesicles: impact of the bioproduction microenvironment. Biotechnol Adv. 2018;36(8):2051–2059.

160. Evaniew N, Noonan VK, Fallah N, Rivers CS, Dvorak MF. Methylenediphosphonate for the treatment of patients with acute spinal cord injuries: response. J Neurotrauma. 2016;33(10):975–976.

161. Sarveazad A, Babahajian A, Bakhtiar M, Soleimani M, Behnam B, Yari A, Akbari A, Yousefifard M, Janzadeh A, Amini N, Agah S, et al. The combined application of human adipose derived stem cells and Chondroitinase ABC in treatment of a spinal cord injury model. Neuropeptides. 2017;61:39–47.

162. Ahuja CS, Mothe A, Khazaei M, Badihiwala JH, Gilbert EA, Behnam B, Yousefifard M, Janzadeh A, Amini N, Agah S, et al. The combined application of human adipose derived stem cells and Chondroitinase ABC in treatment of a spinal cord injury model. Neuropeptides. 2017;61:39–47.

163. Huang et al. Exosomes derived from mesenchymal stem cells promote recovery after spinal cord injury. Int J Clin Exp Pathol. 2015;8(10):11957–11969.

164. Wang YX, Sun JJ, Zhang M, Hou XH, Hong J, Zhou YJ, Song SY, Kwon SP, Hyeon T, et al. Therapeutic efficacy-potentiated and diseased organ-targeting nanovesicles derived from mesenchymal stem cells for spinal cord injury treatment. Nano Lett. 2018;18(8):4965–4975.

165. Wang J, Ding Y, Zeng YS. A new combined therapeutic strategy of governor vessel electro-acupuncture and adult stem cell transplantation promotes the recovery of injured spinal cord. Curr Med Chem 2011;18(33):5165–5171.

166. Kim KT, Kim HJ, Cho DC, Bae JS, Park SW. Substance P stimulates proliferation of spinal neural stem cells in spinal cord injury via the mitogen-activated protein kinase signaling pathway. Spine J. 2015;15(9):2055–2065.

167. Kim HJ, Oh JS, An SS, Pennant WA, Gwak SJ, Kim AN, Han PK, Yoon DH, Kim KN, Ha Y. Hypoxia-specific GM-CSF-overexpressing neural stem cells improve graft survival and functional recovery in spinal cord injury. Gene Ther. 2012;19(5):513–521.

168. Wang J, Chu R, Ni N, Nan G. The Effect of Matrigel as scaffold material for neural stem cell transplantation for treating spinal cord injury. Sci Rep. 2020;10(1):2576.

169. Park SS, Lee YJ, Lee SH, Lee D, Choi K, Kim WH, Kweon OK, Han HJ. Functional recovery after spinal cord injury in dogs treated with a combination of Matrigel and neural-induced adipose-derived mesenchymal Stem cells. Cytotherapy. 2012;14(5):584–597.

170. Ruzicka J, Romanyuk N, Jirakova K, Hejcl A, Janouskova O, Machova LU, Chen JH, Chu R, Ni N, Nan G. The Effect of Matrigel as scaffold material for neural stem cell transplantation for treating spinal cord injury. Sci Rep. 2020;10(1):2576.

171. Fan Z, Liao X, Tian Y, Xuzhu Xi, Nie Y. A prevascularized nerve conduit based on a stem cell sheet effectively promotes the repair of transected spinal cord injury. Acta Biomater. 2020;101:304–313.

172. Zweckberger K, Ahuja CS, Liu Y, Wang J, Fehlings MG. Self-assembling peptides optimize the post-traumatic milieu and synergistically enhance the effects of neural stem cell therapy after cervical spinal cord injury. Acta Biomater. 2016;42:77–89.

173. Nori S, Khazaei M, Ahuja CS, Yokota K, Ahlfors JE, Liu Y, Wang J, Shibata S, Chio J, Hettiaratchi MH, Führmann T, et al. Human oligodendrocyte neural progenitor cells delivered with chondroitinase abc facilitate functional repair of
179. Liu W, Xu B, Xue W, Yang B, Fan Y, Chen B, Xiao Z, Xue X, Sun Z, Shu M, Zhang Q, et al. A functional scaffold to promote the migration and neuronal differentiation of neural stem/progenitor cells for spinal cord injury repair. Biomaterials. 2020;243:119941.

180. Li X, Fan C, Xiao Z, Zhao Y, Zhang H, Sun J, Huang Y, Wu X, Shi J, Chen Y, Dai J. A collagen microchannel scaffold carrying paclitaxel-liposomes induces neuronal differentiation of neural stem cells through Wnt/beta-catenin signaling for spinal cord injury repair. Biomaterials. 2018;183:114–127.

181. Ji WC, Li M, Jiang WT, Ma X, Li J. Protective effect of brain-derived neurotrophic factor and neurotrophin-3 overexpression by adipose-derived stem cells combined with silk fibroin/chitosan scaffold in spinal cord injury. Neurol Res. 2020;42(5):361–371.

182. Tang S, Liao X, Shi B, Qu Y, Huang Z, Lin Q, Guo X, Pei F. The effects of controlled release of neurotrophin-3 from PCL scaffolds on the survival and neuronal differentiation of transplanted neural stem cells in a rat spinal cord injury model. PLoS One. 2014;9(9):e107517.

183. Johnson PJ, Tatara A, McCreedy DA, Shiu A, Sakiyama-Elbert SE. Tissue-engineered fibrin scaffolds containing neural progenitors enhance functional recovery in a subacute model of SCI. Soft Matter. 2010;6(20):5127–5137.

184. Smith DR, Dumont CM, Park J, Ciciriello AJ, Guo A, Tatiren N, Anderson AJ, Shea LD. Polycistronic delivery of IL-10 and NT-3 promotes oligodendrocyte myelination and functional recovery in a mouse spinal cord injury model. Tissue Eng Part A. 2015;3(2):401–413.

185. Zholudeva LV, Lane MA. Transplanting cells for spinal cord repair: who, what, when, where and why? Cell Transplant. 2019;28(4):388–399.

186. Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, Renault-Mihara F, Shimizu A, Koya I, Yoshida R, Kudoh J, et al. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Reports. 2015;4(3):360–373.

187. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24(2):462–471.

188. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012;307(17):1838–1847.